Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia
- PMID: 7318837
- DOI: 10.1007/BF00443255
Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia
Abstract
This study on serum ferritin levels in urinary iron excretion after 12h subcutaneous infusion of desferrioxamine in 10 thalassemia intermedia patients shows that even nontransfusion-dependent patients may have positive iron balance resulting in iron overload from 5 years of age. However, the iron overload found in these patients appears to be much lower than in age matched patients with transfusion-dependent thalassemia major. Iron overload increases with advancing age, as shown by increasing serum ferritin levels and desferrioxamine-induced urinary iron elimination. After a six month trial of 12h continuous subcutaneous desferrioxamine administration there was a significant decline in serum ferritin levels. From this study it seems that iron chelation is indicated in thalassemia intermedia patients over 5 years of age in order to prevent iron accumulation. However, the appropriate treatment schedule should be tailored to the individual needs of each patients, established by close monitoring of serum ferritin levels and desferrioxamine-induced urinary iron elimination.
Similar articles
-
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.Drug Des Devel Ther. 2016 Jan 29;10:465-81. doi: 10.2147/DDDT.S79458. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26893541 Free PMC article. Review.
-
Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.Acta Haematol. 1982;67(1):49-56. doi: 10.1159/000207024. Acta Haematol. 1982. PMID: 6800202
-
Early iron overload in beta-thalassaemia major: when to start chelation therapy?Arch Dis Child. 1982 Dec;57(12):929-33. doi: 10.1136/adc.57.12.929. Arch Dis Child. 1982. PMID: 7181522 Free PMC article.
-
Desferrioxamine induced urinary iron excretion in thalassemia.Indian Pediatr. 1993 Jun;30(6):775-8. Indian Pediatr. 1993. PMID: 8132258
-
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.Hematol Oncol Clin North Am. 2010 Dec;24(6):1109-30. doi: 10.1016/j.hoc.2010.08.015. Hematol Oncol Clin North Am. 2010. PMID: 21075283 Review.
Cited by
-
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.Drug Des Devel Ther. 2016 Jan 29;10:465-81. doi: 10.2147/DDDT.S79458. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26893541 Free PMC article. Review.
-
Splenectomy is significantly associated with thrombosis but not with pulmonary hypertension in patients with transfusion-dependent thalassemia: a meta-analysis of observational studies.Front Med (Lausanne). 2023 Oct 11;10:1259785. doi: 10.3389/fmed.2023.1259785. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37886361 Free PMC article.
-
β-thalassemia intermedia: a clinical perspective.Cold Spring Harb Perspect Med. 2012 Jul;2(7):a013482. doi: 10.1101/cshperspect.a013482. Cold Spring Harb Perspect Med. 2012. PMID: 22762026 Free PMC article. Review.
-
Management of non-transfusion-dependent thalassemia: a practical guide.Drugs. 2014 Oct;74(15):1719-29. doi: 10.1007/s40265-014-0299-0. Drugs. 2014. PMID: 25255924 Review.
-
Thalassaemia intermedia: an update.Mediterr J Hematol Infect Dis. 2009 Aug 29;1(1):e2009004. doi: 10.4084/MJHID.2009.004. Mediterr J Hematol Infect Dis. 2009. PMID: 21415986 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical